18 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28686445	39	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.	Sun Yat-Sen University
27301679	21	Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.	Takeda Pharmaceutical
24758746	36	Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.	Janssen Pharmaceutica
15887951	29	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.	Monash University (Parkville Campus)
19631533	126	Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.	Pfizer
16913726	33	Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.	Università
15006407	15	Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.	Bristol-Myers Squibb Pharmaceutical Research Institute
12668004	76	Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.	Pfizer
32171616	32	Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.	Changzhou University
31235264	13	Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.	Mitsubishi Tanabe Pharma
30986068	112	Structure Overhaul Affords a Potent Purine PI3K? Inhibitor with Improved Tolerability.	TBA
25062128	16	Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).	Amgen
23867165	21	Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5.	Chinese Academy of Sciences
28796496	67	Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.	Takeda Pharmaceutical
28759228	36	Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.	Takeda Pharmaceutical